Arcturus plans Phase II dosing of ARCT-2601 next quarter with top line data in 2H 2027 following 38-fold LUNAR 2.0 potency gain
Open the sourceReported by Seeking Alpha, seekingalpha.com, 6 November 2026
Not scored
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at seekingalpha.com.